• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Thursday, November 19, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Flow Cytometry Workflow Monitors Anti-CD19 CAR-T Cells in Uruguayan Academic Program

by
November 16, 2026
in Health
Reading Time: 2 mins read
0
Flow Cytometry Workflow Monitors Anti-CD19 CAR-T Cells in Uruguayan Academic Program

Flow Cytometry Workflow Monitors Anti-CD19 CAR-T Cells in Uruguayan Academic Program

Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Researchers at Fundación Pérez Scremini in Montevideo, Uruguay, have implemented and operationally assessed a multiparametric flow cytometry workflow designed for monitoring anti-CD19 chimeric antigen receptor T (CAR-T) cells within an academic point-of-care cellular therapy program. Reporting in a methods study published in Frontiers in Hematology, the investigative team established the laboratory protocol to provide direct detection of circulating CAR-T cells, offering information complementary to B-cell aplasia during recipient immune monitoring following cellular therapy.

The established assay was structured to serve two operational checkpoints: product quality control of manufactured CAR-T cells and ongoing post-infusion monitoring in patients. To implement the technical workflow, the researchers utilized an eight-color production panel alongside a locally adapted clinical monitoring panel configured on a thirteen-color DxFLEX cytometer.

Direct identification of the therapeutic cells relied on a biotinylated CD19 CAR Detection Reagent paired with phycoerythrin-conjugated anti-biotin antibodies. During assay optimization, the team evaluated reagent titration, specific gating strategies, and signal-to-noise performance alongside reagent consumption. From these evaluations, an operational working condition of two microliters of CD19 CAR Detection Reagent and two microliters of PE-conjugated anti-biotin was selected to balance staining clarity with reagent stewardship in routine practice.

In parallel with direct cell tracking, the comprehensive monitoring strategy incorporated an assessment of the patient B-cell compartment using a separate ten-color tube to detect B-cell aplasia. Beyond enumerating the presence of CAR-positive cells, the analytical workflow successfully characterized phenotypic subpopulations within the circulating graft, specifically distinguishing the distribution of CD4 and CD8 subsets among the detected CAR-positive lymphocytes.

To interpret low-frequency cell populations with statistical rigor, the team incorporated an analytical sensitivity framework with defined event thresholds. The established criteria specified a limit of blank of 8 events, a limit of detection of 13 events, and a lower limit of quantification of 22 events. The authors noted that these sensitivity benchmarks were adopted directly from previously published validation criteria rather than derived through an independent, complete local recalculation.

The operational workflow was successfully integrated into routine laboratory practice and utilized during the initial clinical phase of Uruguay’s point-of-care cellular therapy program. The investigators concluded that flow cytometry established an integrated, locally available monitoring platform combining direct CAR-T quantification with phenotypic and B-cell profiling, offering practical operational insights for academic cellular therapy initiatives operating under comparable resource and technical implementation conditions.

Subject of Research: Flow cytometric immune monitoring of anti-CD19 CAR-T cells

Article Title: Flow cytometric immune monitoring of anti-CD19 CAR-T cells in an academic point-of-care program in Uruguay: implementation and operational assessment

Article References: Barrios, M., Pereira Pereyra, M. I., Ceriani, V., DAndrea, L., & Castillo, L. (2026). Flow cytometric immune monitoring of anti-CD19 CAR-T cells in an academic point-of-care program in Uruguay: implementation and operational assessment. Frontiers in Hematology, 5, 2007169. https://doi.org/10.3389/frhem.2026.2007169

Image Credits: AI Generated

DOI: 10.3389/frhem.2026.2007169

Keywords: anti-CD19 CAR-T cells, flow cytometry, immune monitoring, B-cell aplasia, cellular therapy, point-of-care program, DxFLEX cytometer, CD19 CAR Detection Reagent, PE-conjugated anti-biotin, reagent titration, gating strategy, limit of blank, limit of detection, lower limit of quantification, CD4/CD8 distribution, T-cell phenotype, Uruguay

News Source: Ophelia Keating. (November 16, 2026). Flow Cytometry Workflow Monitors Anti-CD19 CAR-T Cells in Uruguayan Academic Program. Scienmag.

Tags: anti-CD19 CAR-T cellsB-cell aplasiaCD19 CAR Detection ReagentCD4/CD8 distributioncellular therapyDxFLEX cytometerflow cytometrygating strategyimmune monitoringlimit of blanklimit of detectionlower limit of quantificationPE-conjugated anti-biotinpoint-of-care programreagent titrationT-cell phenotypeUruguay
Share12Tweet7Share2ShareShareShare1

Related Posts

Adjunctive rhBNP Linked to Favorable Cardiac Indices in Non-Randomized PCI Study

Adjunctive rhBNP Linked to Favorable Cardiac Indices in Non-Randomized PCI Study

November 19, 2026
FDA Approvals Reveal Antibacterial Rebound Masking Persistent Lack of Mechanistic Innovation

FDA Approvals Reveal Antibacterial Rebound Masking Persistent Lack of Mechanistic Innovation

November 19, 2026

Low-Virulence Bacteria Fail to Prove Causation in Spinal Disc Degeneration

November 19, 2026

Brain Potentials Fail to Reliably Track Opioid Analgesia During Anesthesia

November 19, 2026

POPULAR NEWS

  • Tryptophan Can Contribute to Seawater Iron Reduction at Lower pH

    Tryptophan Can Contribute to Seawater Iron Reduction at Lower pH

    29 shares
    Share 12 Tweet 7
  • Preserving Cervical Carotid Segments During Autopsy May Facilitate Subsequent Facial Embalming

    29 shares
    Share 12 Tweet 7
  • Adaptive Adversarial Network Boosts Seismic Fault Identification Accuracy Across Surveys

    29 shares
    Share 12 Tweet 7
  • Prenatal Testing Identifies Rare Mosaic Trisomy 14 in Early Severe Fetal Malformations

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Cascaded Neural Networks Optimize Carbonate Reservoir Production Under Geomechanical Stress Limits

Adjunctive rhBNP Linked to Favorable Cardiac Indices in Non-Randomized PCI Study

FDA Approvals Reveal Antibacterial Rebound Masking Persistent Lack of Mechanistic Innovation

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 88 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.